Rheumatoid arthritis: proposal for the use of anti‐microbial therapy in early cases

References

• Harris ED Clinical Features of Rheumatoid Arthritis. In: Ruddy S, Harris, ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. Philadelphia: W.B. Saunders. 2001:967–1000.
   Google Scholar
• MacGregor AJ, Silman AJ Rheumatoid arthritis, classification and epidemiology. In: Klippel JH, Dieppe PA, eds. Rheuma-tology. London: Mosby. 1998:5.2.1–6.
   Google Scholar
• Spector TD. Epidemiology of rheumatic diseases: rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:513–37.
   PubMed Web of Science ®Google Scholar
• Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625–31.
   Google Scholar
• Deighton CM, Walker DJ. The familial nature of rheumatoid arthritis. Ann Rheum Dis 1991;50:62–5.
   PubMed Web of Science ®Google Scholar
• MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30–7.
   PubMed Web of Science ®Google Scholar
• Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976;57:1148–57.
   PubMed Web of Science ®Google Scholar
• Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869–71.
   PubMed Web of Science ®Google Scholar
• Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205–13.
   Google Scholar
• Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DR131 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801–6.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Tokunaga K, Matsuki K, Takeuchi F, Matsuta K, Maeda H, et al. Putative amino acid sequence of HLA-DRB chain contributing to rheumatoid arthritis susceptibility. J Exp Med 1989;169:2263–8.
   PubMedGoogle Scholar
• Nepom GT, Nepom B Genetics of the MHC in rheumatoid arthritis. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby. 1998:5.7.1–12.
   Google Scholar
• O11ier WE, Kennedy LJ, Thomson W, Barnes AN, Bell SC, Bennet D, et al. Dog MHC alleles containing the human RA shared epitope confer susceptibility to canine rheumatoid arthritis. Immunogenetics 2001;53:669–73.
   Google Scholar
• Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J, Dyer PA, et al. "Homozygosity" for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994;37:681–6.
   PubMedGoogle Scholar
• Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al. Twin concordance rates for rheumatoid arthritis: results from a nation-wide study. Br J Rheumatol 1993;32:903–7.
   PubMedGoogle Scholar
• Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. BMJ 2002;324:264–6.
   Google Scholar
• Ebringer A, Ptaszynska T, Corbett M, Wilson C, Macafee Y, Avakian H, et al. Antibodies to Proteus in rheumatoid arthritis. Lancet 1985;ii:305–7.
   Google Scholar
• Khalafpour S, Ebringer A. Cross-reactivity between HLA-DR4 and Proteus mirabilis. Period Biol (Zagreb) 1987;89 Suppl. 1:203.
   Google Scholar
• Goldbach-Mansky R, Senior B, Susan S, Deville C, Hoxworth J, Newkirk M, et al. IgM and IgA antibodies to Proteus mirabilis are associated with early RF positive RA. Arthritis Rheum 2000;43 Suppl. S190.
   Google Scholar
• Deighton CM, Gray SW, Biant AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis 1992;51:1206–7.
   PubMedGoogle Scholar
• Tighe H, Carson DA Rheumatoid factors. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheuma-tology. Philadelphia: W.B. Saunders. 2001:151–60.
   Google Scholar
• Hara Y, Kaneko T, Yoshimura A, Kato I. Serum rheumatoid factor induced by intraperitoneal administration of period-ontopathic bacterial lipopolysaccharide in mice. J Periodontal Res 1996;31:502–7.
   PubMed Web of Science ®Google Scholar
• Ferraro AS, Newkirk MM. Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 1993;92:425–31.
   PubMedGoogle Scholar
• Holmdahl R, Nordling C, Rubin K, Tarkowski A, Klareskog L. Generation of monoclonal rheumatoid factors after immuni-zation with collagen II-anti-collagen II immune complexes. An anti-idiotypic antibody to anti-collagen II is also a rheumatoid factor. Scand J Immunol 1986;24:197–203.
   Google Scholar
• Abedi-Valugerdi M, Ridderstad A, Al-Balaghi S, Moller E. Human IgG rheumatoid factors and RF-like immune complexes induce IgG1 rheumatoid factor production in mice. Scand J Immunol 1995;41: 575–82.
   Google Scholar
• Williams RC, Kunkel HG. Rheumatoid factor, complement and conglutinin aberrations in patients with subacute bacterial endocarditis. J Clin Invest 1962;41:666–75.
   PubMed Web of Science ®Google Scholar
• De Clerck LS. B lymphocytes and humoral immune responses in rheumatoid arthritis. Clin Rheumatol 1995;14 Suppl. 2:14–8.
   Google Scholar
• Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histo-pathological and immunohistochemical study. J Rheumatol 2000;27:1839–47.
   Google Scholar
• Ebringer A, Cunningham P, Ahmadi K, Wrigglesworth J, Hosseini R, Wilson C. Sequence similarity between HLA-DR1 and DR4 subtypes associated with rheumatoid arthritis and Proteus/Serratia membrane haemolysins. Ann Rheum Dis 1992;51:1245–6.
   PubMedGoogle Scholar
• Wilson C, Ebringer A, Ahmadi K, Wrigglesworth J, Tiwana H, Fielder M, et al. Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. Ann Rheum Dis 1995;54:216–20.
   PubMedGoogle Scholar
• Tiwana H, Wilson C, Alvarez A, Abuknesha R, Bansal S, Ebringer A. Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun 1999;67:2769–75.
   PubMedGoogle Scholar
• Takeuchi F, Kosuge E, Matsuta K, Nakano K, Tokunaga K, Juji T, et al. Antibody to a specific HLA-DR131 sequence in Japanese patients with rheumatoid arthritis. Arthritis Rheum 1990;33:1867–8.
   PubMedGoogle Scholar
• Dybwad A, Forre O, Sioud M. Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:437–41.
   Google Scholar
• Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A. Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheumatol 1996;35:592–4.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205–11.
   PubMed Web of Science ®Google Scholar
• Lawson AA, Maclean N. Renal disease and drug therapy in rheumatoid arthritis. Ann Rheum Dis 1966;25:441–9.
   PubMed Web of Science ®Google Scholar
• Tishler M, Caspi D, Aimog Y, Segal R, Yaron M. Increased incidence of urinary tract infection in patients with rheuma-toid arthritis and secondary Sjogren's syndrome. Ann Rheum Dis 1992;51:601–6.
   Google Scholar
• Ebringer A, Wilson C, Ahmadi K, Corbett M, Rashid T, Shipley M, et al. Rheumatoid arthritis as a reactive arthritis to Proteus infection: Prospects for therapy. In: Machtey I, ed. "Sixth International Seminar on the Treatment of Rheumatic Diseases". Prog Rheumatol 1993;5: 77–83.
   Google Scholar
• Senior BW, Anderson GA, Morley KD, Kerr MA. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect 1999;38:99–106.
   PubMedGoogle Scholar
• Wilson C, Thakore D, Isenberg D, Ebringer A. Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int 1997; 16:187–9.
   Google Scholar
• Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self reported incidence and associated costs. Ann Epidemiol 2000;10:509–15.
   Google Scholar
• Nicolle LE Bacteria and Urinary Tract Infections in the Elderly. In: Mulholland SG, ed. Antibiotic Therapy in Urology. Philadelphia: Lippincott-Raven. 1996:39–55.
   Google Scholar
• Sussman M Microbiology and Defences of the Urinary Tract. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DN, Ritz E, Winearls CG (eds). Oxford Textbook of Nephrology. Oxford: Oxford Medical Publications, 1998:1213–30.
   Google Scholar
• Rozalski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997; 61:65–89.
   PubMed Web of Science ®Google Scholar
• Sareneva T, Holthofer H, Korhonen TK. Tissue binding affinity of Proteus mirabilis fimbriae in the human urinary tract. Infect Immun 1990;58:3330–6.
   Google Scholar
• Bahrani FK, Massad G, Lockatell CV, Johnson DE, Russell RG, Warren JW, et al. Construction of an MR/P fimbrial mutant of Proteus mirabilis: Role in virulence in a mouse model of ascending urinary tract infection. Infect Immun 1994;62:3363–71.
   PubMedGoogle Scholar
• Swihart KG, Welch RA. The HpmA hemolysin is more common than HlyA among Proteus isolates. Infect Immun 1990;58:1853–60.
   PubMedGoogle Scholar
• Mobley HTL, Chippendale GR, Swihart KG, Welch RA. Cytotoxicity of the HpmA haemolysin and urease of Proteus mirabilis and Proteus vulgaris against cultured human renal proximal tubular epithelial cells. Infect Immun 1991; 59:2036–42.
   PubMedGoogle Scholar
• Mobley HLT, Hausinger RP. Microbial ureases: Significance, regulation, and molecular characterization. Microbiol Rev 1989;53:85–108.
   PubMedGoogle Scholar
• Fairley KF, Carson NE, Gutch RC, Leighton P, Grounds AD, Laird EC, et al. Site of infection in acute urinary tract infection in general practice. Lancet 1971;ii:615–8.
   Google Scholar
• Holmgren K, Danielson BG, Fellstron B. Infection induced urinary calculi and renal failure. Scand J Urol Nephrol 1987;21:219–23.
   PubMed Web of Science ®Google Scholar
• Mobley HL, Island MD, Massad G. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int 1994;47 Suppl:5129–36.
   Google Scholar
• Wilson C, Senior BW, Tiwana H, Caparros-Wanderley W, Ebringer A. Antibiotic sensitivity and proticine typing of Proteus mirabilis strains associated with rheumatoid arthritis. Rheumatol Int 1998;17:203–5.
   Google Scholar
• Senior BW. The special affinity of particular types of Proteus mirabilis for the urinary tract. J Med Microbiol 1979;12:1–8.
   PubMedGoogle Scholar
• Whiteford JR, Wilson C, Tiwana H, Ebringer A. Genetic diversity in Proteus mirabilis isolates found in the urinary tract of rheumatoid arthritis patients. J Infect 2000;41:245–8.
   PubMedGoogle Scholar
• Ebringer A, Wilson C, Tiwana H. Is rheumatoid arthritis a form of reactive arthritis? J Rheumatol 2000;27:559–63.
   Google Scholar
• Wilson C, Tiwana H, Ebringer A. Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity. Microbes Infect 2000;2:1489–96.
   Google Scholar
• Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068–74.
   PubMed Web of Science ®Google Scholar
• Neumann E, Barnum SR, Tuner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002;46: 934–45.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Symmons D, Harrison B. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheuma-tology (Oxford) 2000;39:835–43.
   PubMedGoogle Scholar
• Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 1995;24: 279–81.
   Google Scholar
• Pisetsky DS, Clair EW. St. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787–90.
   Google Scholar
• Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594–602.
   PubMed Web of Science ®Google Scholar
• Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203–7.
   PubMed Web of Science ®Google Scholar
• Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894–8.
   PubMed Web of Science ®Google Scholar
• Wojtulewski JA, Gow PJ, Walter J, Grahame R, Gibson T, Panayi GS, et al. Clotrimazole in rheumatoid arthritis. Ann Rheum Dis 1980;39:469–72.
   PubMedGoogle Scholar
• Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheuma-toid arthritis; a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983;287:1102–4.
   Google Scholar
• Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001;30:135–42.
   PubMed Web of Science ®Google Scholar
• Fowler PD, Shadforth MF, Crook PR, Lawton A. Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study. Ann Rheum Dis 1984;43:200–4.
   PubMedGoogle Scholar
• Pybus PK. Metronidazole in rheumatoid arthritis. S Afr Med J 1985;67:1039–40.
   PubMed Web of Science ®Google Scholar
• McConkey B, Situnayake RD. Effects of rifampicin with or without isoniazid in rheumatoid arthritis. J Rheumatol 1988;15:46–50.
   PubMed Web of Science ®Google Scholar
• O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. four-year follow-up of a double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:1691–5.
   PubMed Web of Science ®Google Scholar
• Nilsson F, Norberg B, Frederiksen B, Eriksson S. The role of the MA-sensitive leukocyte chemotaxis in rheumatoid arthri-tis. A randomized double-blind clinical trial of griseofulvin treatment. Scand J Rheumatol 1983;12:113–8.
   Google Scholar
• Skinner M, Cathcart ES, Mills JA, Pinals RS. Tetracycline in the treatment of rheumatoid arthritis: A double-blind controlled study. Arthritis Rheum 1971;14:727–32.
   PubMedGoogle Scholar
• Mortiboy D, Palmer RG. Ciprofloxacin and rheumatoid arthritis-Lack of effect. Br J Rheumatol 1989;28:272.
   PubMedGoogle Scholar
• Wolfson JS, Hooper DC. Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmaco-kinetics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob Agents Chemother 1989;33:1655–61.
   PubMedGoogle Scholar
• Sanders WE. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis 1988;10:528–43.
   PubMedGoogle Scholar
• Fang G, Brennen C, Wagener M, Swanson D, Hilf M, Zadecky L, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacoki-netic study. Antimicrob Agents Chemother 1991;35:1849–55.
   PubMed Web of Science ®Google Scholar
• Navaneeth BV, Belwadi S, Suganthi N. Urinary pathogens resistance to common antibiotics: a retrospective analysis. Trop Doct 2002;32:20–2.
   Google Scholar
• Fowler JE Antimicrobial Therapy in the Management of Infected Renal Calculi. In: Mulholland SG (ed). Antibiotic Therapy in Urology. Philadelphia: Lippincott-Raven, 1996:165–86.
   Google Scholar
• Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis 2001;40:51–7.
   PubMed Web of Science ®Google Scholar
• Haugen M, Fraser D, Forre O. Diet therapy for the patients with rheumatoid arthritis? Rheumatology (Oxford) 1999; 38:1039–44.
   PubMedGoogle Scholar
• Bodel PT, Cotran R, Kass EH. Cranberry juice and the antimicrobial action of hippuric acid. J Lab Clin Med 1959;54:881–8.
   Google Scholar
• Papas PN, Brusch CA, Ceresia GC. Cranberry juice in the treatment of urinary tract infections. Southwest Med 1966;47:17–20.
   Google Scholar
• Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type I and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother 1989;33:92–8.
   Google Scholar
• Howell AB, Vorsa N, Der Marderosian AD, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uro-epithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 1998;339:1085–6.
   PubMed Web of Science ®Google Scholar
• Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and non-urinary bacterial isolates. Microbios 1988;55:173–81.
   PubMedGoogle Scholar
• Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994;271:751–54.
   PubMed Web of Science ®Google Scholar
• Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-loganberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322:1571–3.
   PubMed Web of Science ®Google Scholar
• Lowe FC, Fagelman E. Cranberry juice and urinary tract infections: what is the evidence? Urology 2001;57:407–13.
   PubMed Web of Science ®Google Scholar
• Sobel JD. Pathogenesis of urinary tract infections. Host defences. Infect Dis Clin North Am 1987;1:751–72.
   PubMedGoogle Scholar
• Cox CE, Hinman F. Experiments with induced bacteriuria, vesical emptying and bacterial growth on the mechanism of bladder defence to infection. J Urol 1961;86:739–48.
   PubMed Web of Science ®Google Scholar
• Fowler JE. Urinary Tract Infection and Inflammation. Chicago: Year Book Medical Publishers. 1989.
   Google Scholar
• Skoldstam L. Fasting and vegan diet in rheumatoid arthritis. Scand J Rheumatol 1986;15:219–21.
   PubMedGoogle Scholar
• Muller H, Wilhelmi de Toledo F, Resch KL. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol 2001;30:1–10.
   PubMed Web of Science ®Google Scholar
• Kjeldsen-Kragh J, Haugen M, Brochgrevink CF, Laerum E, Eek M, Mowinkel P, et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet 1991;338:899–902.
   Google Scholar
• Kjeldsen-Kragh J, Mellbye OJ, Haugen M, Mollnes TE, Hammer HB, Sioud M, et al. Changes in laboratory variables in rheumatoid arthritis patients during a trial of fasting and one-year vegetarian diet. Scand J Rheumatol 1995;24:85–93.
   Google Scholar
• Kjeldsen-Kragh J, Rashid T, Dybwad A, Sioud M, Haugen M, Forre O, et al. Decrease in anti-Proteus mirabilis but not anti-Escherichia coli antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet. Ann Rheum Dis 1995;54:221–4.
   Google Scholar
• Peltonen R, Nenonen M, Helve T, Hanninen O, Toivanen P, Eerola E. Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol 1997;36:64–8.
   PubMedGoogle Scholar
• Kjeldsen-Kragh J, Kvaavik E, Bottolfs M, Lingaas E. Inhibition of growth of Proteus mirabilis and Escherichia coli in urine in response to fasting and vegetarian diet. APMIS 1995;103:818–22.
   Google Scholar
• Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, et al. Determination of urinary lignans and phytoestrogen metabolites, potential anti-estrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986;25:791–7.
   PubMedGoogle Scholar
• Abuljadayel I, Cox N, Ebringer A. Antibodies to Proteus in rheumatoid arthritis (RA) and to Klebsiella in ankylosing spondylitis (AS) measured by immunofluorescence. Br J Rheumatol 1988;27 Suppl 2:Abst. 2.
   Google Scholar
• Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MS, Cox NL, et al. Antibody response to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatol Int 1997;17:11–6.
   PubMed Web of Science ®Google Scholar
• Deighton CM, Gray SW, Biant AJ, Walker DJ. Anti-Proteus antibodies in rheumatoid arthritis same-sexed sibships. Br J Rheumatol 1992;31:241–5.
   PubMedGoogle Scholar
• Rashid T, Darlington G, Kjeldsen-Kragh J, Forre O, Collado A, Ebringer A. Proteus IgG antibodies and C-reactive protein in English, Norwegian and Spanish patients with rheumatoid arthritis. Clin Rheumatol 1999;18:190–5.
   Google Scholar
• Subair H, Tiwana H, Fielder M, Binder A, Cunningham K, Ebringer A, et al. Elevation in anti-Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. J Rheumatol 1995;22:1825–8.
   PubMedGoogle Scholar
• Senior BW, McBride PD, Morley KD, Kerr MA. The detection of raised levels of IgM to Proteus mirabilis in sera from patients with rheumatoid arthritis. J Med Microbiol 1995;43:176–84.
   PubMedGoogle Scholar
• Rogers P, Hassan J, Bresnihan B, Feighery C, Whelan A. Antibodies to Proteus in rheumatoid arthritis. Br J Rheumatol 1988;27 Suppl. 2:90–4.
   Google Scholar
• Fielder M, Youinou P, Cantagrel A, Wilson C, Ebringer A. Elevation of anti-Proteus antibody titres in rheumatoid arthritis patients from Brest and Toulouse measured by immunofluorescence. Clin Exp Rheumatol 1994;12 Suppl. 2 5104:Abst. C125.
   Google Scholar
• Fielder M, Tiwana H, Youinou P, Le Goff P, Deonarain R, Wilson C, et al. The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Rheumatol Int 1995;15:79–82.
   Google Scholar
• Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1997;24:109–14.
   PubMedGoogle Scholar
• Wanchu A, Deodhar SD, Sharma M, Gupta V, Bambery P, Sud A. Elevated levels of anti-Proteus antibodies in patients with active rheumatoid arthritis. Indian J Med Res 1997;105:39–42.
   PubMedGoogle Scholar
• Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol 1998;25:743–7.
   Google Scholar
• Chou CT, Uksila J, Toivanen P. Enterobacterial antibodies in Chinese patients with rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 1998;16:161–4.
   Google Scholar
• Ushakova MA, Muravijuv UV, Vaneeva NP, Jastrebova NE, Maslov II, Zacharova IE, et al. The Proteus mirabilis antibody levels in patients with rheumatoid arthritis. Rheumatologia 2000;14:Abst.78.
   Google Scholar